New cocktail of five drugs targets Hard-to-Treat bowel cancer
NCT ID NCT04689347
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a combination of five chemotherapy drugs (FLIRT plus bevacizumab) as a first treatment for people with a specific type of metastatic colorectal cancer that has spread. The cancer must have a silenced MGMT gene and be microsatellite stable. The study first finds the safest dose, then checks if it helps control the cancer for at least 9 months. Only 27 people will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fondazione IRCCS Istituto Nazionale dei Tumori
RECRUITINGMilan, Milan, 20133, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Istituto Oncologico Veneto IRCCS
RECRUITINGPadova, PD, 35128, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ospedale Santa Chiara
RECRUITINGPisa, PI, 56126, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
a combination of five drugs: bevacizumab, irinotecan, leucovorin, 5-fluorouracil, and temozolomide
What this could lead to
If successful, this could offer a more effective first-line treatment option for people with a specific genetic subtype of metastatic colorectal cancer that currently has limited targeted therapies.
What could go wrong
This is a very early, small study (27 people) testing safety and dosing. The drug combo is intense and may cause severe side effects. It's not yet known if it will improve survival or quality of life.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.